Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Acting Injectable Risperidone vs Oral Risperidone in Schizophrenia
NCT00240708Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2004
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of risperidone in schizophrenia, sponsored by Janssen Pharmaceutical. Started Jun 2004; status: completed.
02
Drugs
risperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00240708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00240708.